All systems ↗
SYSTEMS / CARDIOVASCULAR
Pressure, flow,
particles & repair.
Follow electrical conduction into contraction, lung oxygenation into tissue delivery, liver lipoprotein production into arterial retention, and vessel injury into clot formation and fibrinolysis.
Educational systems model · not diagnosis, emergency guidance, or individualized treatment advice Evidence reviewed 25 Aug 2026
cardiac cycle 02Oxygen delivery
& venous return 03Blood-pressure
regulation 04Lipoprotein
transport 05Atherosclerosis
& thrombosis 06Coagulation &
fibrinolysis
INTERACTIVE FLOW ATLAS
One circulation.
Six connected views.
Select a pathway, then inspect each stage. Play provides a slow narrated sequence; Important-only keeps the major transitions while Full detail retains every stage.
READYElectrical activation becomes forward flow
Press play or select a stage to begin.
VOICE TRANSCRIPTNarration will follow the visible stage text.
Arrows express educational sequence and influence, not a prediction that every person passes through every disease stage. Acute clot formation can occur in minutes after a plaque has developed over years.
PARTICLE REFERENCE
Cholesterol travels
inside particles.
Particle names describe origin, cargo, and remodeling. LDL-C estimates cholesterol mass within LDL; ApoB more directly reflects the number of circulating atherogenic particles because each VLDL, IDL, LDL, remnant, and Lp(a) particle carries one ApoB molecule.
CONDITION VIEWS
Where regulation
can break down.
Conditions overlap but are not interchangeable. Each card separates the initiating problem, system consequences, urgent branch, and scope limits.
TREATMENT MECHANISMS
Change one pathway.
Watch the tradeoffs.
These are class-level educational summaries. Selection depends on diagnosis, baseline risk, contraindications, interactions, kidney and liver function, bleeding risk, pregnancy considerations, and shared clinical decisions.
STUDY-SPECIFIC ABSOLUTE OUTCOMES
Observed event differences.
Never dose-scaled.
Every row retains the original population, comparator, endpoint, timeframe, and absolute event difference. Different rows must not be compared as if they measured the same benefit or applied to the same person.
| Treatment / study | Population | Endpoint | Control | Treatment | Absolute difference | Follow-up | Limitations & safety context | Source |
|---|
No fraud or intentional data-tampering finding is asserted for the outcome reports in this table. Methodological criticism, sponsor involvement, early stopping, corrections, missing data, and trial limitations must be labeled specifically and are not automatically evidence of fraud.
SOURCE REGISTER
Trace each claim.
Guidelines and regulator documents frame current practice; primary randomized trials support the displayed outcome values; NIH and peer-reviewed physiology sources support the mechanistic maps.